Moderna Gets $590 Million in Federal Funding

Moderna shares soared as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Moderna's stock is down 36.63% due to poor COVID-19 vaccine sales and lack of promising alternatives, but bird flu presents asymmetric upside potential. The company's cost-cutting measures may ...